Advanced Enzyme Technologies Ltd vs J B Chemicals Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 15, 2026

Key Highlights

The Latest Trading Price of Advanced Enzyme Technologies Ltd is ₹ 365.45 as of 15 May 10:58 . The P/E Ratio of Advanced Enzyme Technologies Ltd changed from 26.4 on March 2021 to 23.8 on March 2025 . This represents a CAGR of -2.05% over 5 yearsThe P/E Ratio of J B Chemicals & Pharmaceuticals Ltd changed from 21.6 on March 2021 to 38.3 on March 2025 . This represents a CAGR of 12.14% over 5 years The Market Cap of Advanced Enzyme Technologies Ltd changed from ₹ 3852 crore on March 2021 to ₹ 3120 crore on March 2025 . This represents a CAGR of -4.13% over 5 yearsThe Market Cap of J B Chemicals & Pharmaceuticals Ltd changed from ₹ 9688 crore on March 2021 to ₹ 25253 crore on March 2025 . This represents a CAGR of 21.12% over 5 years The revenue of Advanced Enzyme Technologies Ltd for the Mar '26 is ₹ 210.71 crore as compare to the Dec '25 revenue of ₹ 191.66 crore. This represent the growth of 9.94% The revenue of J B Chemicals & Pharmaceuticals Ltd for the Mar '26 is ₹ 916.21 crore as compare to the Dec '25 revenue of ₹ 1083 crore. This represent the decline of -15.4% The ebitda of Advanced Enzyme Technologies Ltd for the Mar '26 is ₹ 70.57 crore as compare to the Dec '25 ebitda of ₹ 69.07 crore. This represent the growth of 2.17% The ebitda of J B Chemicals & Pharmaceuticals Ltd for the Mar '26 is ₹ 185.93 crore as compare to the Dec '25 ebitda of ₹ 314.1 crore. This represent the decline of -40.81% The net profit of Advanced Enzyme Technologies Ltd changed from ₹ 34.98 crore to ₹ 45.25 crore over 8 quarters. This represents a CAGR of 13.74% The net profit of J B Chemicals & Pharmaceuticals Ltd changed from ₹ 176.83 crore to ₹ 101.37 crore over 8 quarters. This represents a CAGR of -24.29% The Dividend Payout of Advanced Enzyme Technologies Ltd changed from 14.16 % on March 2021 to 56.81 % on March 2025 . This represents a CAGR of 32.03% over 5 yearsThe Dividend Payout of J B Chemicals & Pharmaceuticals Ltd changed from 28.53 % on March 2021 to 36.98 % on March 2025 . This represents a CAGR of 5.33% over 5 years .

About Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Limited (AETL) is largest Indian enzyme company that transformed business globally in the manufacturing and sale of enzymes.
The Company was incorporated, as a Private Company on March 15, 1989 as 'Advanced Biochemicals Private Limited' in Maharashtra.
It thereafter converted the status into a Public Company and the name of the Company was changed to Advanced Biochemicals Limited on May 28, 1992 and further was changed to Advanced Enzyme Technologies Limited via fresh Certificate of Incorporation at RoC, Mumbai on August 19, 2005. In 2011, the company took over Cal-India Foods International, giving the company direct presence in USA. In 2012, the company took over Advanced Supplementary Technologies Corporation for consolidating its presence in USA. Advanced Enzyme Technologies Limited came out with its Initial Public Offer (IPO) of 4,594,875 Equity shares of Rs 10 each at an issue price of Rs 896 per Equity share ( Rs 810 per Equity share for eligible employees), consisting of fresh issue of 560,405 Equity shares and an Offer for Sale of 4,034,470 Equity shares by Selling Shareholders.

About J B Chemicals & Pharmaceuticals Ltd

J B Chemicals & Pharmaceuticals Limited (JBC) was originally promoted and incorporated in Maharashtra by J B Mody as J B Mody Chemicals & Pharmaceuticals on December 18, 1976.
The Company is engaged in the business of manufacturing and marketing of diverse range of pharmaceuticals formulations, herbal remedies and Active Pharmaceutical Ingredients (APIs).
The company has manufacturing units at Thane, Belapur, Ankleshwar, Panoli and Daman.
The bulk drug plant at Panoli and formulation plant at Daman became operational in Apr.'95.
Products like metrogyl, rantac (a ranitidine-based formulation), and nicardia (a cardiac care medicine) form a significant part of the company's sales.

FAQs for the comparison of Advanced Enzyme Technologies Ltd and J B Chemicals & Pharmaceuticals Ltd

Which company has a larger market capitalization, Advanced Enzyme Technologies Ltd or J B Chemicals & Pharmaceuticals Ltd?

Market cap of Advanced Enzyme Technologies Ltd is 4,087 Cr while Market cap of J B Chemicals & Pharmaceuticals Ltd is 34,324 Cr

What are the key factors driving the stock performance of Advanced Enzyme Technologies Ltd and J B Chemicals & Pharmaceuticals Ltd?

The stock performance of Advanced Enzyme Technologies Ltd and J B Chemicals & Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Advanced Enzyme Technologies Ltd and J B Chemicals & Pharmaceuticals Ltd?

As of May 15, 2026, the Advanced Enzyme Technologies Ltd stock price is INR ₹365.0. On the other hand, J B Chemicals & Pharmaceuticals Ltd stock price is INR ₹2137.8.

How do dividend payouts of Advanced Enzyme Technologies Ltd and J B Chemicals & Pharmaceuticals Ltd compare?

To compare the dividend payouts of Advanced Enzyme Technologies Ltd and J B Chemicals & Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.